Considering this, we decided to further investigate the role of wild-type Kras in aggressive, late-stage KRAS-mutant CRC using our recently described metastatic KPN model (villin-creERT2 Kras+/G12DTrp53fl/flRosa26N1icd/+). This evidence concerns the gene KRAS and colorectal carcinoma.